Is p16 immunohistochemistry sufficient to define HPV-related oropharyngeal carcinomas?
Only double-positive tumors (PCR+/p16+) show the prognostic benefit of HPV-related oropharyngeal carcinomas, and the combination of PCR and p16 improves prognostic accuracy and allows for the adequate identification of patients who are candidates for specific therapeutic strategies.